L3VLUP
ProSign in

EYE · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

EYEVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • EYE
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterEYEVRTX
Q3 20206 holders, $358m31 holders, $21.9bn
Q4 20204 holders, $378m30 holders, $18.4bn
Q1 20215 holders, $381m31 holders, $15.4bn
Q2 20215 holders, $517m30 holders, $12.7bn
Q3 20215 holders, $575m35 holders, $10.1bn
Q4 20215 holders, $523m28 holders, $12.4bn
Q1 20226 holders, $632m23 holders, $16.1bn
Q2 20224 holders, $290m25 holders, $18.1bn
Q3 20224 holders, $333m22 holders, $18.4bn
Q4 20225 holders, $380m28 holders, $18.4bn
Q1 20234 holders, $25m26 holders, $21.4bn
Q2 20234 holders, $84m27 holders, $24.7bn
Q3 20235 holders, $59m33 holders, $24.3bn
Q4 20234 holders, $55m32 holders, $28.6bn
Q1 20247 holders, $75m31 holders, $29.8bn
Q2 20244 holders, $38m29 holders, $33.4bn
Q3 20245 holders, $44m27 holders, $33.5bn
Q4 20243 holders, $9.2m26 holders, $28.5bn
Q1 20256 holders, $79m21 holders, $35.4bn
Q2 20258 holders, $161m21 holders, $32.3bn
Q3 20257 holders, $300m22 holders, $25.9bn
Q4 20256 holders, $280m26 holders, $31.8bn
Q1 20266 holders, $263m25 holders, $31.8bn
Q2 20265 holders, $224m26 holders, $34.6bn
EYE

National Vision HLDGS Inc

Holders
3
Reported value
$9.2m
Buyers
3
Sellers
0

Breadth +3 among 94 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$28.5bn
Buyers
14
Sellers
13

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2024

Among the 28 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only EYE (2)

First Eagle Investment Management LLC, Maverick Capital Ltd

Only VRTX (25)

AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Baillie Gifford & Co, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, D. E. Shaw & Co., ExodusPoint Capital Management LP, Fidelity (FMR LLC), Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Voloridge Investment Management LLC, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →